Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
8
Recruiting, any sponsor type, condition "hereditary angioedema"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed102
8 trials
Showing 1 to 8, recently updated first.
- Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema AttacksPivotal-lookingRecruiting
OctapharmaIndustry
NCT06361537 · 124 participants (planned) · Start Apr 30, 2024 · Primary completion Dec 2026
Drug: OCTA-C1-INH · For: Acute Hereditary Angio Edema
Sites: Centennial, Colorado; Farmington Hills, Michigan; Toledo, Ohio · 29 sites in all
- Donidalorsen Treatment in Children With Hereditary AngioedemaPivotal-lookingRecruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07298447 · 20 participants (planned) · Start Apr 21, 2026 · Primary completion Jun 2029
Drug: Donidalorsen · For: Hereditary Angioedema (HAE)
Sites: Santa Monica, California; Miami, Florida; Baton Rouge, Louisiana · 18 sites in all
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyPivotal-lookingRecruiting
Pharvaris Netherlands B.V.Industry
NCT07266805 · 48 participants (planned) · Start Oct 16, 2025 · Primary completion Jun 2027
Drug: Deucrictibant; Placebo and 3 more · For: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Sites: San Diego, California; Walnut Creek, California; St Louis, Missouri · 32 sites in all
KalVista Pharmaceuticals, Ltd.Industry
NCT07654829 · 100 participants (planned) · Start Aug 17, 2026 · Primary completion Nov 29, 2027
Drug: KVD900 600 mg · For: Hereditary Angioedema
Sites: Colorado Springs, Colorado
- STOP-HAE: A Phase 3 Study of ADX-324 in HAEPivotal-lookingRecruiting
ADARx Pharmaceuticals, Inc.Industry
NCT06960213 · 90 participants (planned) · Start Aug 28, 2025 · Primary completion Nov 30, 2027
Drug: ADX-324; Placebo · For: Hereditary Angioedema; HAE; Hereditary Angioedema - Type 1 and 1 more
Sites: Litchfield Park, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 70 sites in all
- Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)Pivotal-lookingRecruiting
ADARx Pharmaceuticals, Inc.Industry
NCT07428499 · 90 participants (planned) · Start Apr 2, 2026 · Primary completion Jun 30, 2030
Drug: ADX-324 Dose Level 1; ADX-324 Dose Level 2 · For: Hereditary Angioedema (HAE); Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2 and 1 more
Sites: Litchfield Park, Arizona; Little Rock, Arkansas; San Diego, California · 48 sites in all
- Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)Pivotal-lookingRecruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT06919003 · 180 participants (planned) · Start Sep 22, 2025 · Primary completion May 30, 2031
Drug: Berinert · For: Kidney Transplant
Sites: Los Angeles, California; Chicago, Illinois; Kansas City, Kansas · 4 sites in all
Institute for Asthma and AllergyResearch network
NCT07046806 · 10 participants (planned) · Start Mar 10, 2025 · Primary completion Apr 1, 2026
Drug: Deucrictibant XR tablet; Placebo comparator to XR tablet and 2 more · For: Hereditary Angioedema (HAE); Angioedema; Bradykinin-mediated Angioedema and 1 more
Sites: Wheaton, Maryland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.